Vamotinib

Overview

Vamotinib (PF-114) is a potent, selective and orally active tyrosine kinase inhibitor. Vamotinib inhibits the autophosphorylation of BCR/ABL and BCR/ABL-T315I. Vamotinib induces apoptosis . Vamotinib shows anti-proliferative and anti-tumor activity. Vamotinib has the potential for the research of resistant philadelphia chromosome-positive (Ph+) leukemia. Vamotinib inhibits ABL series kinases with IC 50 s of 0.49 nM (ABL), 0.78 nM (ABL T315I ), 9.5 nM (ABL E255K ), 2.0 nM (ABL F317I ), 7.4 nM (ABL G250E ), 1.0 nM (ABL H396P ), 2.8 nM (ABL M351T ), 12 nM (ABL Q252H ), and 4.1 nM (ABL Y253F ), respectively. Vamotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Application

Products | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > Bcr-Abl

Product Information

• Catalog No.: HY-147414
• CAS No.: 1416241-23-0
• Molecular Formula: C29H27F3N6O
• Molecular Weight: 532.56
• Purity: 99.89%
• Storage: 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
• Solubility: 2.5 mg/mL (4.69 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source